By submitting this form, you are agreeing to the Terms of Use and Privacy Policy.
Coming Soon
INTRODUCTION
When surgical hemostasis is insufficient or unfeasible, topical hemostatic medications are utilised.
Physical agents, which encourage hemostasis using a passive substrate, and biologically active agents, which improve coagulation at the site of bleeding, are the two primary kinds of topical hemostatic agents.
Factor concentrators, mucoadhesive agents, and procoagulants are the three groups of topical hemostatic agents.
Factor concentrators quickly absorb blood’s water content and concentrate its cellular and protein components, which encourages the formation of clots.
The Global Topical hemostat market accounted for $XX Billion in 2021 and is anticipated to reach $XX Billion by 2030, registering a CAGR of XX% from 2022 to 2030.
With an emphasis on wound closure devices and operating under brands like Dolphin Sutures, Dolphin Mesh, Dolphin Tapes, and Dolphin Stapler, Futura Surgicare Pvt Ltd, a leader in the medical device sector, has been providing excellence in design, manufacture, and distribution for the past 27 years.
By introducing Hemostatic products under the name Hemostax(Oxidized Regenerated Cellulose) under a new vertical Dolphin Hemostats, they have now expanded their product line.
Hemostax Standard is an absorbable hemostat intended to aid surgeons in more effective bleeding control.
Hemostax will absorb blood when it comes into touch with blood, grow over time, and eventually dissolve into a gelatinous substance.
The substance will stick to the wound when pressure is applied temporarily at this spot, essentially closing the ends of the venous capillaries and producing a mechanical hemostatic effect.
Hemostax is made to address persistent, widespread oozing and quickly stop bleeding. It is suitable for use in a variety of surgeries, including several gynecologic, oncologic, cardiovascular, and general procedures since it can be applied readily across vast surfaces.
